

4/PRTS

09486609/486660

PCT/IT98/00231

514 Rec'd PCT/PTO 28 FEB 2000

TRANSGENIC ANIMALS FOR THE STUDY OF BIOLOGICAL, PHYSICAL AND CHEMICAL TOXIC AGENTS

The present invention provides transgenic animals for the study of biological, physical and chemical toxic agents.

5 At present, toxicity tests can be carried out both in vivo and in vitro.

The industrials, the public opinion and the scientific community are strongly interested in the abolition of toxicity tests made on animals and therefore in their replacement with in vitro tests.

10 This target, however, is quite unrealistic at the moment, since no in vitro tests which can replace in vivo tests are available, either now or in the near future.

15 It is well known, in fact, that the substances under in vivo investigation often undergo metabolic modifications, which might significantly alter their toxicity profile, to an extent which would be unpredictable in in vitro tests.

20 On the other hand, in vivo studies always involve animal suffering and sacrifice.

However, it is possible to conceive genetically-engineered animal models which may simplify the determination of the toxicity of various agents and reduce the number of animals involved.

25 Recently, the use of transgenic animals as models for pharmacological studies has been proposed.

For example, EP 0 169 672 B1 describes transgenic animals bearing oncogenes like c-myc, suitable for the

2

study of tumors associated to the expression of such oncogenes, or bearing the human growth hormone gene fused to a metallothionein promoter, whereby, said promoter being an inducible promoter, it is possible to study the effect of the expression, upon induction, of the associated gene on the whole organism (Palmiter et al. (1983) Science 222, 809).

WO 91/15579 describes a method for studying mutagenesis in transgenic animals bearing DNA sequences which can easily be extracted and analysed for mutations.

The present invention provides non-human transgenic animals useful for toxicity studies.

Such animals are characterised in that they have regulatory DNA sequences in some or all their cells, which are sensitive to biological, physical and chemical toxic agents, functionally linked to sequences of reporter genes, whereby the expression of the latter sequences is controlled or induced by said regulatory sequences.

Among the regulatory sequences, the stress-promoter sequences, like the heat shock protein (hsp) promoters, are preferred, but also cytochrome-promoters of the p450-superfamily, as well as those promoters of other genes, like p53 gene, activated by biological, chemical or physical stress, can be cited.

Among suitable reporter genes, the growth hormone gene, which has been used in the experiments described below, is preferred, but also chloramphenicol acetyl transferase (CAT), green fluorescence protein (GFP) and  $\beta$ -galactosidase (LacZ) genes can be suitably employed.

The transgenic animals of the invention can be used

3

in a method for studying the toxicity induced by various agents.

In theory, any animal normally suitable for a toxicity test can be used in the method of the invention. In practice, non-human mammals, particularly  
5 primates and rodents, are preferred.

Mice, in particular, are the most preferred.

Conventional methods can be used for the production of transgenic animals, including, for example, the  
10 microinjection of recombinant DNA into embryonal cells or into pronuclei of one-cell stage embryos, the zygote, embryo cell, somatic cell or animal tissue infection with a virus, in particular with a retrovirus, according to what described, for example, in Hogan et al., Cold  
15 Spring Harbor Laboratory Press, NY, 1986; Palmiter et al., Ann. Rev. Genet., 20: 465-499; 1986; Capecchi, Science, 244: 288-292, 1989.

The method for the in vivo assay of potential toxic compounds according to the present invention, comprises  
20 exposing the animal to a chemical or physical agent for a time sufficient to induce the effect, and simply measuring the reporter gene expression. When the reporter gene encodes a protein secreted in the bloodstream, for instance, its hematic concentration, as  
25 well as other chemical-clinical parameters associated with the effect caused by the activation of the stress promoter, could be detected.

According to the first aspect of the invention, a preferred embodiment is the production of transgenic  
30 mice in which a construct has been inserted, which comprises a hsp promoter fused to growth hormone (GH)

4

gene (transgene), said promoter being described in Dreano et al. (Biotechnology 6:953, 1988 and Gene 49:1-8, 1986) and in Fishbach et al. (Cell Biol. Toxicol. 9:177-188, 1993). The latter publication reports that  
5 the exposure to toxic metals of a stable fibroblast line, engineered with a construct containing the growth hormone gene under the control of hsp promoter, causes the secretion of the reporter gene in the medium.

According to the preferred embodiment of the  
10 invention, the injury caused by the toxic agent is determined as the increase of GH plasma concentration versus the control.

This model has resulted particularly efficient and sensitive, especially in relation with toxic metals, but  
15 it can suitably be used also for other classes of chemical toxic compounds, like endocrine disruptors, as well as for other physical or chemical agents, like radiations and electromagnetic fields.

The main advantages offered by the invention are:  
20 the possibility to diminish animal suffering, since only low amounts of the test substances are used, surely lower than the dosages which could induce animal suffering or death; the reduction of the number of animals used in toxicological tests; the provision of a  
25 model that is absolutely reliable for what concerns the metabolic modifications, which the toxic agents undergo in the organism, the interactions of toxic compounds with various organs and their final effects on cells, including the chronic effects. This model is  
30 particularly useful for test reiterations and allows to monitor the agent's effect during long-lasting

5

treatments using always the same animal, thus eliminating the variability of the individual response. Further, several compounds can be studied using the same animal. Finally, such transgenic models can be used also  
5 for in vivo studies of toxicity kinetics of toxic compounds.

The second aspect of the invention concerns the possibility to obtain primary cultures of cells from different tissues of the transgenic animal, in which a  
10 recombinant DNA construct is integrated as described above, whereby a cell- or tissue-specific toxicity study can be carried out and the intracellular biochemical effects connected to toxicity can be evaluated under controlled conditions and in more detail during  
15 different stages of animal growth.

In this case, the in vitro assay comprises preparing primary cultures in conditions variable depending on the cell type, exposing said cultures to the toxic agent and monitoring the activation of the  
20 stress promoter through detection of the protein encoded by the reporter gene.

Referring to the above described transgenic mice bearing the hsp/GH construct, an embodiment of the second aspect of the invention consists for example in  
25 preparing primary cultures of fibroblasts, kidney, lung or bone marrow cells, hepatocytes or other, in their simultaneous or separate treatment with one or more toxic agents, and in the determination of GH secretion in the medium.

30 If, using the above assay, a tissue or a cell-type resulted sensitive to the toxic agent, a deeper

6

biochemical analysis could be made in order to find which cellular pathways are particularly involved in the toxicity.

Thus, according to a further aspect, the invention provides a method to carry out in vitro toxicity tests on primary cultures of somatic cells derived from a transgenic animal.

#### BRIEF DESCRIPTION OF THE FIGURES

Fig. 1. Panel A: Southern blot analysis of transgenic heterozygous (lanes 1-4) and homozygous mice (lanes 5-7) and a non-transgenic control mouse (lane 8).

Panel B: RT-PCR with hGH specific primers of heat-shock activated liver cells from transgenic mice. Samples: RNA from cultured hepatocytes before (lane 1) and 30 min after (lane 2) heat shock in vitro; RNA from livers before (lane 3) and 30, 60, 90, minutes after heat shock (lanes 4-6). + and - represent the negative and positive controls respectively. Lanes 7 to 10 are the amplifications on non-retrotranscribed liver RNAs performed on the same samples as in lanes 3 to 6. M1: marker V, M2: 1 kb ladder.

Panel C: RT-PCR with HPRT specific primers performed on RNAs from the samples 1 to 6 as in panel B.

Fig. 2: Plasma levels of hGH (pg/ml) measured at different times in transgenic mice after thermal stress. Values represent the mean  $\pm$  SE; the number of mice tested for each time period is indicated by the number above each bar.

Fig. 3: Mean hGH plasma levels (pg/ml)  $\pm$  SE observed in transgenic mice injected i.p. with PBS and with various inorganic toxic compounds at the indicated

7

doses. Besides controls, are indicated: Rb: rubidium chloride; Hg: methylmercurium chloride; Cu: copper sulphate; Cd: cadmium chloride; As: sodium arsenite (2 doses)(below each bar is given the number of tested mice). The levels of significance are: \* $p < 0.05$ ; \*\* $p < 0.01$ ; \*\*\* $p < 0.005$

Fig. 4: Mean  $\pm$  SE of plasma hGH levels observed in transgenic mice subjected to two consecutive treatments, according to the following schema:

10

Group	First treatment (T <sub>1</sub> )	Second treatment (T <sub>2</sub> )	Time Interval (T <sub>1</sub> -T <sub>2</sub> )
As <sub>1</sub>	As	As	10 days
As <sub>2</sub>	Cd	As	2 months
As <sub>3</sub>	Rb	As	2 months
Cu	Cu	Cu	2 months
Control	untreated	untreated	

20

The following examples better illustrate the invention:

#### EXAMPLE 1

#### Production and characterization of a transgenic mouse lineage

25

Transgenic mice were produced according to standard techniques (Hogan et al., "Manipulating the mouse embryo: a laboratory manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y., 1986), by microinjecting 1-cell stage embryo pronuclei with a 1.4 kb EcoRI DNA fragment from p17hGH construct (described in Dreano et al., Biotechnology 6:953, 1988 and Gene

30

8

49:1-8, 1986), containing the human growth hormone cDNA as reporter gene, fused to the control region of the human Hsp70 promoter.

5 Mice were screened by Southern blot and/or PCR performed on tail DNA according to standard techniques. PCR was performed with the following primers: hGHL:GTGCAGTTCCTCAGGAGTGT; hGHR: CGAACTTGCTGTAGGTCTGC.

10 The amplification product was 171 bp long. Amplification conditions (35 cycles) were: 94°C for 20 sec, 58°C for 30 sec and 72°C for 20 sec. Heterozygous males and females were crossed and the homozygous progeny was identified by Southern blot, based on the intensity of the transgenic bands; their homozygosity was confirmed by checking the offspring when the  
15 homozygous male was mated to a non-transgenic partner. The mice used for the in vitro and in vivo experiments were always derived from a homozygous male bred with a non-transgenic CD-1 female.

20 Total RNA was extracted from different tissues (liver, spleen, lung, kidney, blood) of transgenic and control mice, according to standard techniques (Sambrook et al., "Molecular cloning: a laboratory manual", Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). Southern and Northern blot were performed  
25 according to standard techniques.

In order to evaluate the basal value of non-induced expression of the transgene, mice were analysed with Northern blot and with RT-PCR.

30 No expression was detected in lung, kidney, spleen, liver and peripheral blood lymphocytes of non-treated animals or of animals not-exposed to heat shock. The hGH



9

level in non-treated mice (control) was generally under the test detection limits, and when it was determined, it never exceeded 10 pg/ml.

#### EXAMPLE 2

##### 5       In vivo heat shock treatment.

Eight transgenic mice obtained according to example 1 and four non-transgenic control mice were subjected to in vivo heat shock at 44°C for 30 min. Six additional unexposed transgenic mice were tested. Aliquots of blood  
10       were taken before and 1, 3, 5, 7, and 24 hours after the heat shock.

In transgenic mice (Fig. 2) a specific increase of plasma hGH was detected with a peak three hour after treatment.

15       These results suggest that the integrated transgene does not affect in vivo the normal responsiveness of hsp promoter.

#### EXAMPLE 3

a)   Inducibility of the hsp70/hGH transgene expression  
20       in vivo by sodium arsenite and methylmercurium chloride.

Male transgenic mice obtained as described in example 1 were weighed, anesthetized with ether and injected intraperitoneally (i.p.) with NaAsO<sub>2</sub> dissolved in PBS, at a final dose of 2.5 or 5 mg/kg, or with 3.5  
25       mg/kg CH<sub>3</sub>HgCl dissolved in PBS. Control transgenic mice were injected with the same volume of PBS (about 200 µl/mouse).

Blood samples were recovered before injection and 1, 3, 5, 7 and 24 hours after treatment.

30       hGH plasma levels at different times and doses are shown in Fig. 3.

10

Both the tested doses of  $\text{NaAsO}_2$  gave a clear and statistically significant response.

The response peaked after 3-5 hours and turned to the basal level 24 hours after injection.

5         $\text{CH}_3\text{HgCl}$  gave hGH peaks after 5-7 hours and baseline hGH values 24 hours after injection.

b) Following the same procedure as described in a), hGH inducibility was evaluated in mice treated with rubidium chloride (18.5 mg/kg, c), copper sulfate (9  
10 mg/kg, d) and cadmium chloride (4.7 mg/kg, e).

Results are reported in Fig. 3.

#### EXAMPLE 4

Inducibility of the hsp70/hGH transgene expression in vivo by repeated injections of toxic compounds.

15        Initially, 13 mice were treated as follows:

5 mice with As, 3 mice with Cd, 2 mice with Rb, 3 mice with Cu. After a period of 10 days to 2 months, the former three groups of mice were re-inoculated with As, the latter with Cu.

20        Blood samples were taken before and 3-5 hours after injection, i.e. at the times of highest response.

As shown in Fig. 4, after the first administration of the compound, the mice showed a response comparable to that observed in groups of mice treated as in example  
25        3.

When retested after 10-60 days, a similar hGH increase was observed.

#### EXAMPLE 5

Embryonic fibroblast primary cultures-in vitro toxicity tests.  
30

Homozygous transgenic mice obtained as described in

11

example 1 were crossed with CD-1 females. After 14 days, embryonic fibroblasts (EMFIS) were recovered from the fetuses according to the technique described by Robertson E.J., IRL Press, Oxford, 77-88, 1987.

5           Cells were cultured in DMEM supplemented with 10% FCS and antibiotics (pen/strep), in an incubator (CO<sub>2</sub>:5%, 100% humidity). Culture medium was replaced every second day with pre-warmed (37°C) fresh culture medium. The cells were expanded for two passages and  
10 then frozen at -80°C. For each experiment, cells were thawed, plated in 10 cm Petri dishes, left to grow and then re-seeded on 12 well plates until confluence.

To evaluate the toxic effect of the compounds, cells were treated by substituting the culture medium  
15 with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions. Cells were exposed to the toxic compound for either 5 or 24 hours and then the medium was replaced with fresh control medium for an additional 24 hours. At the end of  
20 the treatment, culture media were collected and assayed for hGH secretion by enzyme immunoassay.

Each treatment was performed in triplicate and the hGH determination was repeated twice for each plate. The results are expressed as pg of hGH/10<sup>6</sup> cells. The  
25 sensitivity of this method was approximately 2-4 pg/ml.

As shown in the table, calcium and rubidium, known for their lack of toxicity at the tested concentrations, do not provoke hGH release in the medium.

On the contrary, a significant release is induced  
30 after 24 hours of chrome exposure, while copper gives a low response after 24 hours at the highest

12

concentrations. On the contrary, mercurium does not induce hGH release from fibroblasts at each tested concentration.

Finally, arsenic and cadmium, as expected, showed  
5 clearly toxic.

#### EXAMPLE 6

Primary hepatocytes cultures-in vitro toxicity tests.

Transgenic male mice 8 weeks old were anesthetized  
10 and their livers were perfused as described in Clerici et al., Mut. Res., 227:47-51, 1989, in order to collect hepatocytes. Hepatocytes were then seeded on 24 well plates ( $2 \times 10^5$  cells/well) and cultured in William's E medium supplemented with antibiotics (pen/strep) and 10%  
15 FCS for 2 hours in order to allow them to attach to the bottom of the Petri dishes. The supernatant was then removed and the adherent cells were treated with the compounds dissolved in the medium.

To evaluate the toxic effect of the compounds,  
20 cells were treated by substituting the culture medium with fresh pre-warmed serum-free medium containing the toxic compounds at the chosen final dilutions.

As shown in the table, calcium and rubidium do not induce hGH release by mature hepatocytes.

25 Chrome treatment induces a high response after 24 hours, while copper treatment causes release either after 5 or 24 hours at each concentration.

Mercurium induces a response at concentrations higher than  $5 \times 10^{-5}$  M, while arsenic and cadmium show  
30 extremely toxic.

#### EXAMPLE 7

13

In vitro toxicity tests on kidney, lung and bone-marrow primary cultures.

Kidney and lung cells were recovered as described by Campbell, J. A. et al. ("Sister chromatid exchange analysis of mice following in vitro exposure to vinyl carbonate", In vitro Cell. Dev. Biol. 22: 443:448, 1986).

Briefly, kidneys were removed from the same animals subjected to liver perfusion, washed 3 times in PBS additioned with antibiotics and minced in 0.5 mm pieces with a sterile scalpel. After 1 hour of incubation in trypsin/collagenase (100U/ml) solution, the suspension was centrifuged twice for 5 min. at 50xg, plated in 100 mm Falcon dishes and cultured in McCoy's medium with 20% FCS, 2mM Glutamine and Pen/strep.

In order to collect lung cells, after liver perfusion the chest cavity was opened after liver perfusion to access the lungs. The trachea was cut with a scalpel and a 22-gauge catheter was inserted into the trachea to perfuse the lungs with trypsin/collagenase solution for 5 min. in order to help the disaggregation of this tissue. The cells were then trypsinized, seeded in 24 wells and left to grow until confluence in McCoy's medium with 20% FCS, 2mM Glutamine and antibiotics.

In order to prepare bone marrow primary cultures, bone marrow cells were flushed from the cavity of femurs and tibias with a syringe containing the culture medium. Cells were plated in 12 well plates with McCoy's medium with 20% FCS, 2mM Glutamine and antibiotics, and left to grow until the stromal cells reached confluence.

To evaluate the toxic effect of the compounds, the

WO 99/11772

PCT/IT98/00231

14

same procedure was followed as in the above examples 5 and 6.

Results are reported in the Table.

Table  
(A) Determination of hGH (pg/10<sup>6</sup> cells) release and primary transgenic cultures viability after 5-hour treatment

Compounds	Primary lines	hGH release		Viability			
		10 <sup>-5</sup> M	5x10 <sup>-5</sup> M	10 <sup>-4</sup> M	5x10 <sup>-4</sup> M	10 <sup>-4</sup> M	5x10 <sup>-4</sup> M
hepatocytes	CaCl <sub>2</sub>	nd	nd	nd	nd	+	+
	RbCl	nd	nd	nd	nd	+	+
	CrCl <sub>3</sub>	/	nd	nd	nd	+	+
	CuSO <sub>4</sub>	/	nd	80	66	+	+
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	65	94	65	+/-	-
	CH <sub>3</sub> HgCl	nd	nd	nd	/	+/-	/
	CdCl <sub>2</sub>	309	452	57	14	+/-	-
	NaAsO <sub>2</sub>	100	224	nd	/	+/-	/
Embryonic fibroblast	CaCl <sub>2</sub>	/	nd	nd	nd	+	+
	RbCl	/	nd	nd	nd	+	+
	CrCl <sub>3</sub>	/	nd	nd	nd	+	+
	CuSO <sub>4</sub>	/	nd	6	12	+	+
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	9	nd	nd	nd	+/-	-
	CH <sub>3</sub> HgCl	/	nd	nd	nd	+/-	/
	CdCl <sub>2</sub>	250	85	45	nd	+/-	-
	NaAsO <sub>2</sub>	nd	113	19	nd	+/-	/

continues

16

CaCl <sub>2</sub>	Kidney	/	nd	nd	nd	+	+	+
RbCl	cells	/	57	nd	nd	+	+	+
CrCl <sub>3</sub>		/	nd	15	nd	+	+	+/-
CuSO <sub>4</sub>		/	nd	nd	nd	+	+	+/-
K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>		nd	nd	nd	/	+/-	+/-	/
CH <sub>3</sub> HgCl		10	nd	nd	/	+/-	+/-	/
CdCl <sub>2</sub>		nd	nd	nd	/	-	-	/
NaAsO <sub>2</sub>		22	17	28	/	+/-	-	/
CaCl <sub>2</sub>	Lungs	/	nd	127	202	+	+	+
RbCl	cells	/	28	191	71	+	+	+
CrCl <sub>3</sub>		/	92	122	166	+	+	+
CuSO <sub>4</sub>		/	nd	nd	184	+	+	+/-
K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>		nd	nd	nd	/	-	-	/
CH <sub>3</sub> HgCl		27	nd	nd	/	-	-	/
CdCl <sub>2</sub>		nd	31	11	/	-	-	/
NaAsO <sub>2</sub>		nd	37	249	/	+/-	-	/

hGH levels in untreated cells medium (controls) were not measurable after 5-24-hour incubation.

nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability;

- = 100% dead



(B) Determination of hGH (pg/10<sup>6</sup> cells) release and primary transgenic cultures after 24-hour treatment.

Compounds	Primary lines	hGH release			Vitality		
		10 <sup>-5</sup> M	5x10 <sup>-5</sup> M	10 <sup>-4</sup> M	10 <sup>-5</sup> M	10 <sup>-4</sup> M	5x10 <sup>-4</sup> M
hepatocytes	CaCl <sub>2</sub>	nd	nd	nd	+	+	+
	RbCl	nd	nd	nd	+	+	+
	CrCl <sub>3</sub>	/	36	20	/	+	-
	CuSO <sub>4</sub>	/	12	61	/	+	+/-
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	nd	nd	-	+	-
	CH <sub>3</sub> HgCl	nd	63	103	+/-	-	/
	CdCl <sub>2</sub>	nd	nd	17	+/-	-	-
	NaAsO <sub>2</sub>	270	19	5	+	+/-	/
Embryonic fibroblast	CaCl <sub>2</sub>	/	nd	nd	/	+	+
	RbCl	/	nd	nd	/	+	+
	CrCl <sub>3</sub>	/	8	10	/	+	+
	CuSO <sub>4</sub>	/	nd	10	/	+	+
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	nd	nd	+/-	-	-
	CH <sub>3</sub> HgCl	/	nd	nd	/	-	-
	CdCl <sub>2</sub>	181	108	41	-	-	-
	NaAsO <sub>2</sub>	19	380	37	+/-	+/-	-

continues

106201 09998460

Kidney cells	CaCl <sub>2</sub>	/	nd	nd	nd	/	+	+	+
	RbCl	/	nd	nd	nd	/	+	+	+
	CrCl <sub>3</sub>	/	nd	nd	nd	/	+	+	+/-
	CuSO <sub>4</sub>	/	nd	nd	450	/	+	+	-
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	nd	nd	/	-	-	-	/
	CH <sub>3</sub> HgCl	nd	nd	nd	/	-	-	-	/
	CdCl <sub>2</sub>	nd	81	110	/	+/	-	-	/
	NaAsO <sub>2</sub>	300	nd	40	/	+	+	-	/
	CaCl <sub>2</sub>	/	nd	nd	nd	/	+	+	+/-
	RbCl	/	20	110	114	/	+	+	+/-
Lungs cells	CrCl <sub>3</sub>	/	200	199	35	/	+	+	+/-
	CuSO <sub>4</sub>	/	81	132	901	/	+	+	-
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	13	92	nd	/	-	-	-	/
	CH <sub>3</sub> HgCl	nd	164	nd	/	-	-	-	/
	CdCl <sub>2</sub>	64	196	415	/	+/	-	-	/
	NaAsO <sub>2</sub>	20	55	nd	/	+/	-	-	/
	CaCl <sub>2</sub>	/	nd	nd	nd	/	+	+	+/-
	RbCl	/	nd	20	110	/	+	+	+/-
	CrCl <sub>3</sub>	/	nd	21	21	/	+	+	+/-
	CuSO <sub>4</sub>	/	nd	127	145	/	+	+	-
Bone marrow cells	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	38	127	/	+/	-	-	/
	CH <sub>3</sub> HgCl	nd	42	165	/	+/	-	-	/
	CdCl <sub>2</sub>	nd	nd	nd	/	+/	-	-	/
	NaAsO <sub>2</sub>	nd	nd	nd	/	+	+	+	/
	CaCl <sub>2</sub>	/	nd	51	nd	/	+	+	+/-
	RbCl	/	nd	20	128	/	+	+	+/-
	CrCl <sub>3</sub>	/	nd	21	21	/	+	+	+/-
	CuSO <sub>4</sub>	/	nd	127	145	/	+	+	-
	K <sub>2</sub> Cr <sub>2</sub> O <sub>7</sub>	nd	38	127	/	+/	-	-	/
	CH <sub>3</sub> HgCl	nd	42	165	/	+/	-	-	/

hGH levels in untreated cells medium (controls) were not measurable after 24-hour incubation.

nd = undetectable; / = not determined; + = with 100% viability; with 30-70% viability;

- = 100% dead